Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

(2022) Amalia Gastaldelli et al.   Lancet Diabetes & Endocrinology

Accuracy of Dexcom G6 Continuous Glucose Monitoring in Non–Critically Ill Hospitalized Patients With Diabetes

(2021) Georgia M. Davis et al.   DIABETES CARE

Association of HbA1c With All-cause Mortality Across Varying Degrees of Glycemic Variability in Type 2 Diabetes

(2021) Jingyi Lu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

(2021) Bernhard Ludvik et al.   LANCET

Time in range: a new parameter to evaluate blood glucose control in patients with diabetes

(2020) Monica Andrade Lima Gabbay et al.   Diabetology & Metabolic Syndrome

Glycemic variability – the danger of a physiologically stable metric

(2020) Tadej Battelino et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial

(2020) Antonio Ceriello et al.   Cardiovascular Diabetology

Time in Range in Relation to All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes: A Prospective Cohort Study

(2020) Jingyi Lu et al.   DIABETES CARE

Fasting Glucose Variation Predicts Microvascular Risk in ACCORD and VADT

(2020) Jin J Zhou et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range

(2019) Tadej Battelino et al.   DIABETES CARE

Optimal Sampling Duration for Continuous Glucose Monitoring to Determine Long-Term Glycemic Control

(2018) Tonya D. Riddlesworth et al.   Diabetes Technology & Therapeutics

Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials

(2018) Roy W. Beck et al.   DIABETES CARE

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

(2018) Juan Pablo Frias et al.   LANCET

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

(2018) Tamer Coskun et al.   Molecular Metabolism

Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report: Table 1

(2016) David M. Maahs et al.   DIABETES CARE

Exenatide once weekly improved 24-hour glucose control and reduced glycaemic variability in metformin-treated participants with type 2 diabetes: a randomized, placebo-controlled trial

(2016) Juan P. Frías et al.   DIABETES OBESITY & METABOLISM

Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy

(2016) Johan Jendle et al.   DIABETES OBESITY & METABOLISM

Longitudinal tobit regression: A new approach to analyze outcome variables with floor or ceiling effects

(2009) Jos Twisk et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials?

(2009) Guanghan F. Liu et al.   STATISTICS IN MEDICINE